



PHARMACOKINETIC AND PHARMACODYNAMIC DRUG INTERACTIONS OF EPROSARTAN AND GLIBENCLAMIDE IN HEALTHY ALBINO WISTAR RATS

V Rama Krishna*, S Prashanth, P Goverdhan, J Vidya Sagar

Vaagdevi College of Pharmacy, Vishwambara Educational Society, Ramnagar, Hanmakonda, Warangal, A.P, India.

*Corresponding author's E-mail: veldhandi@gmail.com

Accepted on: 26-09-2011; Finalized on: 20-12-2011.

ABSTRACT

The study was intended to find out the pharmacokinetic and pharmacodynamic drug interaction of eprosartan, a prototype drug used to treat diabetic nephropathy with glibenclamide in healthy Albino Wistar rats following single and multiple dosage treatment. Therapeutic doses (TD) of glibenclamide, TD of eprosartan were administered to the animals. The blood glucose levels were estimated by GOD/POD method and the plasma glibenclamide concentrations were estimated by a sensitive RP HPLC method to calculate pharmacokinetic parameters. In single dose study the percentage reduction of blood glucose levels and glibenclamide concentrations of rats treated with both eprosartan and glibenclamide were significantly increased when compared with glibenclamide alone treated rats and the mechanism behind this interaction may be due to inhibition of P-glycoprotein mediated transport of glibenclamide by eprosartan, but in multiple dose study the percentage reduction of blood glucose levels and glibenclamide concentrations were reduced and it is may be due to inhibition of P-glycoprotein mediated transport and induction of CYP2C9, the enzyme through which glibenclamide is metabolised. In the present study there is a Pharmacokinetic and Pharmacodynamic interaction between eprosartan and glibenclamide was observed. The possible interaction involves both P-gp and CYP enzymes. To investigate this type of interactions in pre-clinically are helpful to avoid drug-drug interactions in clinical situation.

Keywords: Diabetic nephropathy, P-glycoprotein, Drug interactions.

INTRODUCTION

Diabetes mellitus is the most common cause of nephropathy worldwide, and is becoming an increasing burden in countries in which the prevalence of obesity is rising.¹ Hence, with oral hypoglycemic drugs, the addition of drugs used to treat Diabetic Nephropathy is necessary in these patients. In such a situation, there may be chances for drug-drug interaction between these drugs.

Sulfonylureas are the drugs of choice in the treatment of type II diabetes. Currently glibenclamide, a second generation sulfonylurea, was preferred in therapy because of its selective inhibitory activity toward pancreatic K⁺ATP channels.² It is well established that sulfonylureas produce insulin secretion and improve tissue utilization of glucose at cellular level which was responsible for lowering of blood glucose level. The sulfonylureas and related drugs used in type II diabetes stimulate insulin by closing K⁺ATP channels in pancreatic β cells.

Diabetic nephropathy is often renal failure, and the renal problem is frequently resistant to conventional treatments. Treatment with Angiotensin converting enzyme blockers for a few weeks or months, Losartan, Eprosartan, Enalapril, or Catopril in combination with codeine phosphate can be useful along with adjustment of glycemic control.³⁻⁵

The concomitant administration of glibenclamide with eprosartan in patients suffering with diabetic nephropathy may result in drug-drug interaction with enhanced/decreased glibenclamide activity, which is

unwanted. The study is planned to establish the safety of the drug combination in animal models with respect to blood glucose level and find out the mechanisms responsible for the interaction if any.⁶⁻⁹

MATERIALS AND METHODS

Drugs and Chemicals

Glibenclamide is the gift sample from Alka Pharmaceuticals (Hyderabad, India) and Eprosartan is the gift sample from M.S.N Formulations (Hyderabad, India) Glucose kits of Excel diagnostics were procured from local suppliers. The HPLC grade methanol and acetonitrile of Qualigens fine chemicals, Mumbai were procured from local chemical suppliers. All other chemicals used were of analytical grade.

Animals

Experiments were performed with Albino Wistar rats of either sex procured from Mahaveera Enterprises (Hyderabad, A.P., India), weighing between 180 to 210gms. The animals were housed in colony cages (four per cage) under conditions of standard lighting, temperature (22±1°C) and humidity for at least one week before the beginning of experiment, to adjust to the new environment and to overcome stress possibly incurred during transit. During this period, they had free access to food and water. The experiments were planned after the approval of Institutional Animal Ethical Committee (IEAC), Vaagdevi College of Pharmacy, Warangal, and A.P., India.



Pharmacokinetic and pharmacodynamic studies in healthy Albino Wistar rats

Albino Wistar rats of either sex were randomly distributed into four groups of six animals in each group. Before experiment all animals were fasted for 18 hours and water ad libitum, water was withdrawn during experiment. After collection of initial blood samples, drugs were administered in the following order.

Group I— Control (0.2 ml of 0.5% Carboxymethylcellulose [CMC] sodium; p.o.).

Group II — Glibenclamide (3.6mg/kg; p.o.).

Group III — Pretreated with Eprosartan (10.8mg/kg) followed by Glibenclamide (3.6mg/kg) after 30 minutes.

Group IV — Pretreated with Eprosartan (10.8mg/kg) for 14 days, 15th day administration of Eprosartan (10.8mg/kg) followed by Glibenclamide (3.6mg/kg) after 30 minutes.

In this study, blood was collected from orbital sinuses after phenobarbital sodium (0.2%) anesthesia using heparinized capillaries into a micro centrifugation tubes contain a 0.1ml of 0.2% citric acid as an anticoagulant at 1, 2, 4, 6, and 8h after treatment. Plasma was separated by centrifugation and stored at -20°C until further analysis. These samples are used to analyze for both blood glucose levels and glibenclamide. Blood glucose levels are estimated by GOD-POD method and glibenclamide was estimated by a sensitive RP HPLC method respectively.

Bioanalytical Method

Plasma glibenclamide concentrations were determined with a validated high-performance liquid chromatography (HPLC) method. Briefly, the HPLC system consisted of a Waters 717 plus Autosampler (Waters Co, Milford, Massachusetts), a Waters 501 pump (Waters Co), and a 785 UV Detector (Applied Biosystems, Foster City, California) operated at 253nm. The stationary phase was a Waters Symmetry C18 column (250 × 4.6 mm, 5 μm , Waters Co). The mobile phase used was 25 mM sodium phosphate/acetonitrile (65:35, v/v, pH = 3.5) at a flow rate of 1.0 mL/min. Glibenclamide and an internal standard (glipizide) were isolated from plasma by liquid-liquid extraction with methanol. The organic phase was separated and evaporated, and the remaining residue was reconstituted with 250 μL of mobile phase before applied to the HPLC system. The method was validated and found to be linear over the concentration range of 0.1 to 10 $\mu\text{g}/\text{mL}$. Using a linear weighted least squares regression, the lower limit of quantitation (LLOQ) was 0.1 $\mu\text{g}/\text{mL}$. The intra-assay and interassay coefficients of variation (%CV) for the 4 quality control standards (0.25, 2.00, 8.00, and 30.0 $\mu\text{g}/\text{mL}$) were $\leq 10.2\%$ and 4.9%, respectively. The accuracy ranged between 96.7% and 99.1% for the plasma samples.

Pharmacokinetic Analysis

The pharmacokinetic parameters of glibenclamide were calculated using a sophisticated tool known as Win Nonlin (4.1) and the parameters includes half-life ($T_{1/2}$), clearance (CL_F), volume of distribution (V_F), C_{max} , T_{max} and area under the curve (AUC).

Statistical Analysis

The data was expressed as mean \pm standard deviation (SD). The significance was determined by applying one way ANOVA.

RESULTS


In the present study the plasma glibenclamide levels and pharmacokinetic parameters of glibenclamide like AUC, $T_{1/2}$, CL_F , V_F , C_{max} , and T_{max} were altered significantly with single- and multiple-dose treatments of eprosartan in healthy rats and the results were shown in Table 1 and Figure 1 respectively.

Table 1: Comparison of Pharmacokinetic parameters of glibenclamide (3.6mg/kg) following pretreatment with eprosartan (10.8mg/kg) by oral administration in healthy rats (n=6)

Parameter	Glb	Glb+ Epr (1 st day)	Glb+Epr (15 th day)
AUC($\mu\text{g}/\text{ml}/\text{h}$)	12.96 \pm 4.88	20.95 \pm 3.61***	9.56 \pm 2.13 ^{NS}
$K_{HL}(\text{h}^{-1})$	2.24 \pm 0.04	2.848 \pm 0.24**	3.00 \pm 0.25**
$CL_F(\text{ml}/\text{h})$	42.31 \pm 12.37	24.51 \pm 4.51*	54.23 \pm 10.85**
T_{max} (h)	3.24 \pm 0.06	4.10 \pm 0.34***	4.33 \pm 0.36***
$C_{\text{max}}(\mu\text{g}/\text{ml})$	1.46 \pm 0.51	1.86 \pm 0.24 ^{NS}	0.80 \pm 0.12**
$V_F(\text{ml})$	235.51 \pm 45.82	147.73 \pm 21.98**s	273.3 \pm 41.5 ^{NS}

*Significant at $P < 0.05$, **Significant at $P < 0.01$, ***Significant at $P < 0.001$ compared to glibenclamide control


Figure 1: Comparison of Mean \pm SD plasma concentration-time profile of glibenclamide (3.6mg/kg) following pretreatment with eprosartan (10.8mg/kg) by oral administration in healthy rats (n=6)



The hypoglycemic activity of Glibenclamide was enhanced in combination treated group than individual Glibenclamide treated group (46.62 \pm 3.20% to 53.17 \pm 4.30%) at fourth hour of initial day of treatment. But in multiple dosages the combination produced less hypoglycemic activity with maximum reduction of 38.13 \pm 3.71% on 15th day at fourth hour and the results were shown in Figure 2 respectively.



Figure 2: Comparison of Mean \pm SD percentage reduction of blood glucose-time profile of glibenclamide (3.6mg/kg) following pretreatment with eprosartan (10.8mg/kg) by oral administration in healthy rats



DISCUSSION

Drug interactions are usually seen in clinical practice and the mechanisms of interactions are evaluated usually in animal models. We studied the influence of eprosartan on the pharmacodynamics and pharmacokinetics of glibenclamide at therapeutic doses in healthy rats. The healthy rat model served to quickly identify the interaction. Glibenclamide is known to produce hypoglycemic activity by pancreatic (stimulating insulin secretion by blocking K^+ channels in the pancreatic β cells) and extra pancreatic¹⁰ (increasing tissue uptake of glucose) mechanisms. Eprosartan enhanced hypoglycemic effect of glibenclamide in single dosage but on multiple dosages it reduced hypoglycemic effect of glibenclamide in healthy rats.

There was significant rise in plasma glibenclamide levels and pharmacokinetic parameters like AUC, $T_{1/2}$, clearance, V_{dss} , V_{darea} , C_{max} , and T_{max} of glibenclamide with single dose treatment of eprosartan. But on multiple dosages the plasma glibenclamide levels and pharmacokinetic parameters were significantly reduced.

In single dose studies the results showed that the co administration of eprosartan significantly increased the AUC of glibenclamide by 38.11%. Furthermore, the $T_{1/2}$, which reflects the elimination of glibenclamide, was also significantly altered by eprosartan. These results suggest that the increased plasma concentrations of glibenclamide in eprosartan treated rats would be caused by an increase in glibenclamide bioavailability. The possible mechanism behind this type of interaction at pharmacokinetic level may be due to Inhibition of P-glycoprotein mediated transport of glibenclamide by eprosartan in gastrointestinal tract and in renal tubules.

In multiple dosages, the results showed that the co administration of eprosartan significantly decreased the AUC of glibenclamide by 30.86%, and the results suggest that the decreased plasma concentrations of glibenclamide in eprosartan treated rats would be caused

by a decrease in glibenclamide bioavailability. The mechanism involved in this interaction may be the Induction of CYP2C9, the enzyme responsible for metabolize glibenclamide by eprosartan and this type of interaction only observed in multiple doses but not on single dose because. The induction process involves the synthesis of new proteins and it depends upon the half-life of inducer (eprosartan). In present study eprosartan is an inducer with half-life more than 35hr's and to synthesize new proteins by eprosartan it takes more than one week in rats.¹¹

CONCLUSION

The interaction observed appears to be pharmacokinetic interaction at absorption, metabolic and excretion levels and also at pharmacodynamic level. Hence, the combination of glibenclamide and eprosartan should be contraindicated or used with caution in a clinical situation.

REFERENCES

- Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas studies on cloned cardiac and β - cell KATP channels. *Diabetes* 1998; 47:1412-8.
- Bruns L. Neuropathic paralysis in diabetes mellitus [German]. *Berl Klin Wochenschr* 1890;27:509-15.
- Said G, Thomas PK. Proximal diabetic neuropathy. *Diabetic Neuropathy* 1999; 2:474-80.
- Said G, Catherine GG, Lacroix C, Moulounguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. *Ann Neurol* 1994; 35:559-69.
- Said G, Lacroix C, Lozeron P, Ropert A, Plante V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. *Brain* 2003; 126:376-85.
- Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. *J Neurol Neurosurg Psychiatry* 1997; 40:1072-82.
- Malik RA, Tesfave S, Newrick PG, Walker D, Rajbhandari SM, Siddique I. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. *Diabetologia* 2005; 48:578-85.
- Caselli A, Spallone V, Marfia GA, Battista C, Pachatz C, Veves A. Validation of the nerve axon reflex for the assessment of small nerve fibre dysfunction. *J Neurol Neurosurg Psychiatry* 2006; 77:927-32.
- Thamotharampillai K, Albert KF, Bennetts B, Craig ME, Cusmano J, Silink M. Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphisms. *Diabetes Care* 2006; 29:2053-57.
- Johnson PC, Doll BS, Cromey MS. Pathogenesis of diabetic neuropathy. *Ann Neurol* 1986; 19:450-57.
- King RM, Llewelyn G, Thomas PK, Gilbey SG, Watkins PJ. Diabetic neuropathy: Abnormalities of Schwann cells and perineurial basal laminae implications for diabetic vasculopathy. *Neuropathol Appl Neurobiol* 1989; 15:339-55.

